Trial 3P-23-3


A Phase 1b Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ATP150/ATP152, VSV-GP154 and Ezabenlimab (BI 754091) in Patients with KRAS G12D/G12V Mutated Pancreatic Ductal Adenocarcinoma

Type: Treatment
Phase: Phase I
Status: Open to Accrual
Treatments: Immunotherapy, Vaccine
Randomized: Yes
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Heinz Josef Lenz, M.D.
Other Trial Staff:  Charlean Ketchens, R.N., Jiayi Jiang, D.M., Noureddine Miloud, D.M., Yanli Wang, D.M., Rabia Rehman, Coordinator, Angela Smith Bryant, Coordinator, Young-Wook Kim, Coordinator, Syed Husein, D.M., Diane Chun, Coordinator, Liza Pizarro, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.